SEARCH

SEARCH BY CITATION

References

  • 1
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32 (Suppl. 5): S1129.
  • 2
    Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 152438.
  • 3
    Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia – a puzzling and conflicting story. Nephrol Dial Transpl 2005; 20: 1621.
  • 4
    Stenvinkel P, Ketteler M, Johnson RJ et al. Interleukin-10, IL-6 and TNF-α: important factors in the altered cytokine network of end-stage renal disease – the good, the bad and the ugly. Kidney Int 2005; 67: 121633.
  • 5
    Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 64858.
  • 6
    Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transpl 2002; 17: 16848.
  • 7
    Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793808.
  • 8
    Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett 2003; 190: 12533.
  • 9
    Dong C, Yoon W, Goldsmith-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 2002; 132: 2406S9S.
  • 10
    Erlinger T, Platz E, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 58590.
  • 11
    Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 2006; 42: 7047.
  • 12
    Karimi M, Johansson S, Ekström TJ. Using LUMA: a luminometric based assay for global DNA-methylation. Epigenetics 2006; 1: 458.
  • 13
    Karimi M, Johansson S, Stach D et al. LUMA (LUminometric Methylation Assay) – a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res 2006; 312: 198995.
  • 14
    National Kidney Foundation. KDOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000; 35 (Suppl. 2): S1S140.
  • 15
    Stenvinkel P, Heimbürger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899911.
  • 16
    Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 4416.
  • 17
    Detsky AS, McLaughlin JR, Baker JP et al. What is subjective global assessment of nutritional status? J Parenter Enterol Nutr 1987; 33: 6503.
  • 18
    Teitell M, Richardson B. DNA methylation in the immune system. Clin Immunol 2003; 109: 25.
  • 19
    Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003; 163: 15516.
  • 20
    Jang TJ, Kim DI, Shin YM, Chang HK, Yang CH. p16(INK4a) promoter hypermethylation of non-tumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int J Cancer 2001; 93: 62934.
  • 21
    Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. Interleukin-6 regulation of the human DNA metyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 2001; 276: 3950811.
  • 22
    Hodge DR, Peng B, Cherry JC et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promotor methylation. Cancer Res 2005; 65: 467382.
  • 23
    Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signalling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101: 27848.
  • 24
    Zoccali C, Mallamaci F. Homocysteine and risk in end-stage renal disease: a matter of context. Kidney Int 2006; 69: 2046.
  • 25
    Yi P, Melnyk S, Pogribna M, Pogrinby IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000; 275: 2931823.
  • 26
    Ingrosso D, Cimmino A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinemia in patients with uremia. Lancet 2003; 361: 16939.
  • 27
    Post WS, Goldschmidt-Clermont PJ, Wilhide CC et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43: 98591.
  • 28
    Zhu S, Goldsmith-Clermont PJ, Dong C. Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. Circulation 2005; 112: 135361.
  • 29
    Lund G, Andersson L, Lauria M et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004; 279: 2914754.
  • 30
    Kaysen GA, Dublin JA, Müller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int 2000; 58: 34652.
  • 31
    Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 17918.